James F. Howard

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

57h-index13.1kcitations374works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Myasthenia Gravis and Thymoma(222), Peripheral Neuropathies and Disorders(112), Parkinson's Disease and Spinal Disorders(51), Antifungal resistance and susceptibility(41), Cancer Treatment and Pharmacology(39)

Publications368 total

Risk of Infection Following Clearance of Immunoglobulin G by Plasma Exchange in Myasthenia Gravis
Muscle & Nerve·2026Open Access
FcRn inhibitors: A new era in neurotherapeutics
Handbook of clinical neurology·2026
Patient Outcomes Among Medicare Beneficiaries With Guillain–Barré Syndrome
Journal of the Peripheral Nervous System·2025Open Access
The Disparities in Myasthenia Gravis Clinical Trial Enrollment in the United States and Canada
Muscle & Nerve·2025Open Access
Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?
UNC Libraries·2025Open Access
Advancing Care in Myasthenia Gravis: What Can We Learn From the Multiple Sclerosis Community?
Neurology and Therapy·2025Open Access
TCT-69 Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials
Journal of the American College of Cardiology·2025
TCT-452 The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study (ORBITA-STAR)
Journal of the American College of Cardiology·2025
3390 Effect of zilucoplan on myasthenia gravis-specific outcome subdomain scores in RAISE: a phase 3 study
2025Open Access
Reply to the Letter to the Editor: The Role of Patient‐Reported Symptoms in Standardizing <scp>MGFA</scp> Class 0 and <scp>MGFA</scp> ‐ <scp>PIS</scp>
Muscle & Nerve·2025
Characterizing Guillain-Barré Risk Factors Among Traditional Medicare Beneficiaries
INQUIRY The Journal of Health Care Organization Provision and Financing·2025Open Access
482PME&amp;MGopen™ digital biomarkers help track generalized myasthenia gravis symptoms
Neuromuscular Disorders·2025
Durability of Response to B‐Cell Maturation Antigen‐Directed <scp>mRNA</scp> Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology·2025· 5 citedOpen Access
Classical Complement Pathway Inhibition in a “Human‐On‐A‐Chip” Model of Autoimmune Demyelinating Neuropathies
UNC Libraries·2025Open Access
Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
UNC Libraries·2025Open Access
Eculizumab improves fatigue in refractory generalized myasthenia gravis
UNC Libraries·2025Open Access
First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab
Journal of the Neurological Sciences·2025· 2 citedOpen Access
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study
Therapeutic Advances in Neurological Disorders·2025· 2 citedOpen Access
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
UNC Libraries·2025Open Access
Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
UNC Libraries·2025Open Access
page 1 of 19Next →

Frequent Co-authors

Michael Benatar(13), Renato Mantegazza(11), Tuan Vu(11), Richard J. Nowak(10), Richard J. Barohn(9), Mamatha Pasnoor(9), Henry J. Kaminski(9), Kimiaki Utsugisawa(8), Hiroyuki Murai(8), Ted M. Burns(8), Srikanth Muppidi(8), Gary M. Franklin(8), Manisha Chopra(8), John Vissing(7), John T. Kissel(7), Richard A. Lewis(7), A. J. Sumner(7), Tahseen Mozaffar(7), Mazen M. Dimachkie(7), Donald B. Sanders(7)